Healthy and thriving: ARPM, MAPP companies maintain safety as top priority

FierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test

Endpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 study

BioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haul

Endpoints NewsKardigan raises $400M in IPO to back three clinical-stage cardio drugs

Endpoints NewsBiogen makes up to $1B deal for secretive anti-inflammatory biotech

FierceBiotech‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game

SchunkHealthy and thriving: ARPM, MAPP companies maintain safety as top priority - Rubber News

10x Genomics Blog10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus

Clinical OMICsHave Microbubbles Burst Through the Barriers of Genetic Medicine Delivery?

AgilentAgilent (A) Has a Consumables-and-Service Analytical Platform Bigger Than a Biotech-Funding Proxy - AlphaStreet

Clinical OMICsOLE Identified as a Potential Alzheimer’s Therapy Targeting Microglia

Endpoints NewsFDA gives rejected drugs another chance in post-Makary era